Zhou Xuan-Peng, Sun Luan-Biao, Liu Wen-Hao, Zhu Wu-Ming, Li Lin-Chun, Song Xin-Yuan, Xing Jian-Peng, Gao Shuo-Hui
China-Japan Union Hospital of Jilin University, Changchun, Jilin 130000, PR China.
The Chinese University of Hong Kong, New Territories 999077, Hong Kong.
Ageing Res Rev. 2025 Feb;104:102637. doi: 10.1016/j.arr.2024.102637. Epub 2024 Dec 9.
Alzheimer's disease (AD) is a progressive, degenerative disorder of the central nervous system. Despite extensive research conducted on this disorder, its precise pathogenesis remains unclear. In recent years, the microbiota-gut-brain axis has attracted considerable attention within the field of AD. The gut microbiota communicates bidirectionally with the central nervous system through the gut-brain axis, and alterations in its structure and function can influence the progression of AD. Consequently, regulating the gut microbiota to mitigate the progression of AD has emerged as a novel therapeutic approach. Currently, numerous studies concentrate on the intrinsic relationship between the microbiota-gut-brain axis and AD. In this paper, we summarize the multifaceted role of the gut microbiota in AD and present detailed therapeutic strategies targeting the gut microbiota, including the treatment of AD with Traditional Chinese Medicine (TCM), which has garnered increasing attention in recent years. Finally, we discuss potential therapeutic strategies for modulating the gut microbiota to alleviate the progression of AD, the current challenges in this area of research, and provide an outlook on future research directions in this field.
阿尔茨海默病(AD)是一种中枢神经系统的进行性退行性疾病。尽管对这种疾病进行了广泛研究,但其确切发病机制仍不清楚。近年来,微生物群-肠道-脑轴在AD领域引起了相当大的关注。肠道微生物群通过肠道-脑轴与中枢神经系统进行双向通信,其结构和功能的改变会影响AD的进展。因此,调节肠道微生物群以减轻AD的进展已成为一种新的治疗方法。目前,许多研究集中在微生物群-肠道-脑轴与AD之间的内在关系上。在本文中,我们总结了肠道微生物群在AD中的多方面作用,并提出了针对肠道微生物群的详细治疗策略,包括近年来越来越受到关注的用中药治疗AD。最后,我们讨论了调节肠道微生物群以减轻AD进展的潜在治疗策略、该研究领域当前的挑战,并展望了该领域未来的研究方向。